Midazolam ODT is under clinical development by Melt Pharmaceuticals and currently in Phase I for Sedation. According to GlobalData, Phase I drugs for Sedation have a 75% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Midazolam ODT’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Midazolam ODT overview

Midazolam (MELT-210) is under development for procedural sedation. The drug candidate is administered through sublingual route in the form of orally disintegrating tablet (ODT). It acts by targeting gamma-aminobutyric acid type A receptor subunit (GABA(A) receptor or GABR).

Melt Pharmaceuticals overview

Melt Pharmaceuticals is dedicated to the development of innovative approaches to procedural sedation and analgesia for short-term medical operations. The company is headquartered in United States.

For a complete picture of Midazolam ODT’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.